应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02511 君圣泰医药-B
未开盘 09-02 15:59:29
3.140
+0.000
0.00%
最高
3.225
最低
3.070
成交量
21.05万
今开
3.125
昨收
3.140
日振幅
4.94%
总市值
21.04亿
流通市值
21.04亿
总股本
6.70亿
成交额
66.46万
换手率
0.03%
流通股本
6.70亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
君圣泰医药-B授出约235万份购股权及奖励股份
公告速递 · 09-01 21:55
君圣泰医药-B授出约235万份购股权及奖励股份
君圣泰医药-B(02511)授出204.045万份购股权及30.67万份奖励
智通财经 · 09-01 21:51
君圣泰医药-B(02511)授出204.045万份购股权及30.67万份奖励
君圣泰医药-B(02511.HK)授出204.045万份购股权及30.67万份奖励
智通财经 · 09-01 21:51
君圣泰医药-B(02511.HK)授出204.045万份购股权及30.67万份奖励
君圣泰医药-B(02511.HK)公布中期业绩 拥有人应占亏损约1.46亿元 同比增长21.43%
智通财经 · 08-31 21:32
君圣泰医药-B(02511.HK)公布中期业绩 拥有人应占亏损约1.46亿元 同比增长21.43%
君圣泰医药-B2026年上半年营收0.00百万元，经调整净亏损1.56亿元
公告速递 · 08-31 21:27
君圣泰医药-B2026年上半年营收0.00百万元，经调整净亏损1.56亿元
股东张晓雷增持君圣泰医药(02511)1000万股 每股作价3.50港元
智通财经网 · 08-14
股东张晓雷增持君圣泰医药(02511)1000万股 每股作价3.50港元
君圣泰医药-B（02511）将于8月31日召开董事会审议2026年中期业绩
公告速递 · 08-14
君圣泰医药-B（02511）将于8月31日召开董事会审议2026年中期业绩
君圣泰医药-B(02511)存仓市值总计2.87亿港元 其中股东向中信证券经纪香港存入5260.1万股
智通财经 · 08-10
君圣泰医药-B(02511)存仓市值总计2.87亿港元 其中股东向中信证券经纪香港存入5260.1万股
君圣泰医药-B完成配售9871万股新股
新浪港股 · 08-09
君圣泰医药-B完成配售9871万股新股
君圣泰医药-B(02511)：5日内累涨超30%，折价配售是妙手回春还是饮鸩止渴？
智通财经 · 08-08
君圣泰医药-B(02511)：5日内累涨超30%，折价配售是妙手回春还是饮鸩止渴？
君圣泰医药-B：8月7日发行98,710,000股 占已发行股本17.28%
公告速递 · 08-07
君圣泰医药-B：8月7日发行98,710,000股 占已发行股本17.28%
君圣泰医药-B（02511）完成约2.25亿港元一般性授权配售 逾9,871万股新股发行价2.28港元/股
公告速递 · 08-07
君圣泰医药-B（02511）完成约2.25亿港元一般性授权配售 逾9,871万股新股发行价2.28港元/股
君圣泰医药-B(02511.HK)完成配售9871万股 净筹约2.224亿港元
智通财经 · 08-07
君圣泰医药-B(02511.HK)完成配售9871万股 净筹约2.224亿港元
君圣泰医药-B7月股份变动月报表：股本维持不变
公告速递 · 08-03
君圣泰医药-B7月股份变动月报表：股本维持不变
君圣泰医药-B(02511)拟折让约12.31%发行合共最多9900万股配售股份
智通财经 · 07-31
君圣泰医药-B(02511)拟折让约12.31%发行合共最多9900万股配售股份
君圣泰医药-B(02511.HK)拟折让约12.31%发行合共最多9900万股配售股份
智通财经 · 07-31
君圣泰医药-B(02511.HK)拟折让约12.31%发行合共最多9900万股配售股份
君圣泰医药-B(02511)拟配售9,900万股 预计募资净额约2.23亿元港元
公告速递 · 07-31
君圣泰医药-B(02511)拟配售9,900万股 预计募资净额约2.23亿元港元
君圣泰医药-B(02511)：HTD1801随机对照临床研究获积极评价
智通财经 · 07-10
君圣泰医药-B(02511)：HTD1801随机对照临床研究获积极评价
君圣泰医药-B6月无新增发行或股份变动
公告速递 · 07-02
君圣泰医药-B6月无新增发行或股份变动
格隆汇2026中期策略峰会“All in 硅基新纪元”暨“金格奖”——卓越公司榜单全部揭晓！
格隆汇 · 06-29
格隆汇2026中期策略峰会“All in 硅基新纪元”暨“金格奖”——卓越公司榜单全部揭晓！
加载更多
公司概况
公司名称：
君圣泰医药-B
所属市场：
SEHK
上市日期：
--
主营业务：
君圣泰医药是一家生物制药公司，专注于就代谢及消化系统疾病的治疗发现、开发及商业化多功能及多靶点疗法。该公司自主开发了多个候选产品的产品管线，涵盖代谢和消化疾病的多种适应症，其中部分产品处于临床阶段。该公司的核心产品HTD1801（小檗碱熊去氧胆酸盐）是一种新分子实体，作为肠肝抗炎代谢调节剂，靶向调节对人体代谢过程中至关重要的多个通路，包括与代谢及消化系统疾病相关的通路。该公司在美国、中国大陆、香港和澳大利亚开展业务。
发行价格：
--
{"stockData":{"symbol":"02511","market":"HK","secType":"STK","nameCN":"君圣泰医药-B","latestPrice":3.14,"timestamp":1788335969011,"preClose":3.14,"halted":0,"volume":210500,"delay":0,"changeRate":0,"floatShares":670000000,"shares":670000000,"eps":-0.51,"marketStatus":"未开盘","change":0,"latestTime":"09-02 15:59:29","open":3.125,"high":3.225,"low":3.07,"amount":664617,"amplitude":0.049363,"askPrice":3.18,"askSize":1500,"bidPrice":3.14,"bidSize":17000,"shortable":0,"etf":0,"ttmEps":-0.405,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788399000000},"marketStatusCode":0,"adr":0,"listingDate":1703174400000,"exchange":"SEHK","adjPreClose":3.14,"openAndCloseTimeList":[[1788312600000,1788321600000],[1788325200000,1788336000000]],"volumeRatio":0.5937940762976122,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02511","defaultTab":"news","newsList":[{"id":"1146598951","title":"君圣泰医药-B授出约235万份购股权及奖励股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1146598951","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146598951?lang=zh_cn&edition=full","pubTime":"2026-09-01 21:55","pubTimestamp":1788270933,"startTime":"0","endTime":"0","summary":"2026年9月1日，君圣泰医药-B公告，根据于2025年6月27日采纳的「2025年股份激励计划」，公司当天向合资格参与者授出合计2,347,199份权益，其中包含2,040,450份购股权及306,749份奖励股份。\\n\\n购股权方面，公司向4名承授人授出2,040,450份购股权，其中644,171份授予3名雇员参与者，1,396,279份授予集团首席医学官Filip Surmont博士。\\n\\n本次购股权的行使价为每股3.154港元，高于授出当日收市价每股3.14港元及前5个营业日平均收市价每股3.154港元。购股权行使期自授出日期起计10年。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664985474","title":"君圣泰医药-B(02511)授出204.045万份购股权及30.67万份奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=2664985474","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664985474?lang=zh_cn&edition=full","pubTime":"2026-09-01 21:51","pubTimestamp":1788270683,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君圣泰医药-B(02511)发布公告，于2026年9月1日，公司根据2025年股份激励计划授出204.045万份购股权予4名承授人;及30.67万份奖励予1名承授人，分别占截至授出日期已发行及发行在外股份总数(不包括库存股份)约0.30%及0.05%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664746854","title":"君圣泰医药-B(02511.HK)授出204.045万份购股权及30.67万份奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=2664746854","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664746854?lang=zh_cn&edition=full","pubTime":"2026-09-01 21:51","pubTimestamp":1788270683,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02511","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663912006","title":"君圣泰医药-B(02511.HK)公布中期业绩 拥有人应占亏损约1.46亿元 同比增长21.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663912006","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663912006?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:32","pubTimestamp":1788183120,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137279270","title":"君圣泰医药-B2026年上半年营收0.00百万元，经调整净亏损1.56亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137279270","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137279270?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:27","pubTimestamp":1788182840,"startTime":"0","endTime":"0","summary":"2026年上半年，君圣泰医药-B披露的半年报显示，公司在报告期内并未产生主营业务收入。经调整净亏损为1.56亿元，上年同期为1.01亿元，亏损同比扩大约54.4%。财报指出，报告期内研发成本为36.8百万元，上年同期为106.4百万元，同比减少65.4%；行政开支为43.5百万元，上年同期为21.6百万元，同比增加101.4%。因仍在临床及注册环节推进，未实现主营业务收入。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"君圣泰医药-B2026年上半年营收0.00百万元，经调整净亏损1.56亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659214692","title":"股东张晓雷增持君圣泰医药(02511)1000万股 每股作价3.50港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2659214692","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659214692?lang=zh_cn&edition=full","pubTime":"2026-08-14 19:12","pubTimestamp":1786705929,"startTime":"0","endTime":"0","summary":"8月13日，股东张晓雷增持君圣泰医药(02511)1000万股，每股作价3.5港元，总金额约为3500万港元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260814/20260814191419_56922.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260814/20260814191419_56922.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","02511","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198920739","title":"君圣泰医药-B（02511）将于8月31日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1198920739","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198920739?lang=zh_cn&edition=full","pubTime":"2026-08-14 16:45","pubTimestamp":1786697158,"startTime":"0","endTime":"0","summary":"君圣泰医药-B（02511）8月14日公告称，公司董事会会议拟于2026年8月31日（星期一）举行，届时将审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜，同时处理其他相关事项。\n公告显示，董事会成员包括执行董事刘利平博士、于萌女士；非执行董事朱迅博士、马立雄先生、江峰先生；以及独立非执行董事李靖博士、孔德伟先生、陈明宇先生。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658660573","title":"君圣泰医药-B(02511)存仓市值总计2.87亿港元 其中股东向中信证券经纪香港存入5260.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658660573","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658660573?lang=zh_cn&edition=full","pubTime":"2026-08-10 08:17","pubTimestamp":1786321077,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，8月7日，君圣泰医药-B(02511)出现仓位异动，存仓市值总计2.87亿港元，占比14.73%。该公司股东将股票存入中信证券经纪香港5260.1万股，持股比例增加5.57%。君圣泰医药截至2025年12月31日止年度业绩显示，该集团取得其他收入1900.7万元，同比减少72.04%；公司拥有人应占亏损2.45亿元，同比减少35.84%；每股亏损0.51元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2495084118.USD","BK0276","LU1781817850.SGD","LU1255011170.USD","600030","BK1564","LU1655091616.SGD","LU1997245177.USD","LU1720050803.USD","BK0196","BK1147","LU1580142542.USD","LU2289578879.USD","LU1328615791.USD","LU1997245094.SGD","BK0183","BK0012","LU2580892789.USD","BK1516","LU2148510915.USD","02511","BK1161","BK1521","LU0405327494.USD","06030","LU0405327148.USD","BK0028","LU1794554557.SGD","LU1064131003.USD","BK0188","LU2580892862.HKD","LU1997244956.HKD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658793426","title":"君圣泰医药-B完成配售9871万股新股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658793426","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658793426?lang=zh_cn&edition=full","pubTime":"2026-08-09 10:04","pubTimestamp":1786241040,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端君圣泰医药-B（02511）公布，2026年8月7日完成配售9871万股新股，每股配售价2.28港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-08-09/doc-inimsssr1943204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657620993","title":"君圣泰医药-B(02511)：5日内累涨超30%，折价配售是妙手回春还是饮鸩止渴？","url":"https://stock-news.laohu8.com/highlight/detail?id=2657620993","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657620993?lang=zh_cn&edition=full","pubTime":"2026-08-08 19:03","pubTimestamp":1786186992,"startTime":"0","endTime":"0","summary":"2025年6月26日，君圣泰医药-B发布公告，宣布拟每股作价2.21港元折让约15%配售股份。2026年8月7日，君圣泰医药宣布新一轮配售9871万股已完成，净筹约2.22亿港元。当日公司股价大幅收涨16.84%，并在5个交易日内累涨30.77%。这也是君圣泰连续两年选择折价配售的主要原因之一。在安全性方面，HTD1801表现出良好的耐受性，严重不良事件发生率为3.8%，低于达格列净组的4.4%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180948291","title":"君圣泰医药-B：8月7日发行98,710,000股 占已发行股本17.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180948291","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180948291?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:56","pubTimestamp":1786092984,"startTime":"0","endTime":"0","summary":"君圣泰医药-B（股份代号：02511）于2026年8月7日发布翌日披露报表，宣布根据日期为2026年7月31日的配售协议及一般授权，于8月7日向市场发行98,710,000股新股，占发行前已发行股本的约17.28%。发行价格为每股2.28港元。发行完成后，公司已发行股本增至670,035,668股，库藏股数保持为0股。\n公司在公告中确认是次发行已获得董事会正式授权，并遵守相关上市规则及法律法规。上述公告由执行董事兼行政总裁刘利平博士签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"君圣泰医药-B：8月7日发行98,710,000股 占已发行股本17.28%","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183181864","title":"君圣泰医药-B（02511）完成约2.25亿港元一般性授权配售 逾9,871万股新股发行价2.28港元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=1183181864","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183181864?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:52","pubTimestamp":1786092739,"startTime":"0","endTime":"0","summary":"2026年8月7日，君圣泰医药-B公告称，公司已完成根据一般性授权进行的新股份配售。此次配售的全部条件已达成，具体情况如下：。本次共向不少于六名独立承配人配售98,710,000股新股，每股配售价2.28港元。配售所得款项总额约为2.25亿港元，扣除相关费用及佣金后，公司实际可得净额约2.22亿港元。股本变动：配售完成后，君圣泰医药-B已发行股份由571,325,668股增至670,035,668股，新增股份占配售完成前已发行股份约17.28%，占扩大后已发行股份约14.73%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657977616","title":"君圣泰医药-B(02511.HK)完成配售9871万股 净筹约2.224亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657977616","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657977616?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:51","pubTimestamp":1786092665,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167009735","title":"君圣泰医药-B7月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1167009735","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167009735?lang=zh_cn&edition=full","pubTime":"2026-08-03 11:11","pubTimestamp":1785726719,"startTime":"0","endTime":"0","summary":"君圣泰医药-B2026年8月3日发布公告，披露截至2026年7月31日的证券变动月报表。报告期内，公司法定/注册股本及已发行股份数未发生任何增减变动。根据公告，君圣泰医药-B法定/注册股本数为1,000,000,000股，面值每股USD 0.0001，法定/注册股本总额维持USD 100,000不变。公告显示，君圣泰医药-B在报告期内无股份期权、权证、可转换债券或其他与发行人股份相关的相关变动及安排。截至2026年7月31日，公司总股本保持不变。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655361066","title":"君圣泰医药-B(02511)拟折让约12.31%发行合共最多9900万股配售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2655361066","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655361066?lang=zh_cn&edition=full","pubTime":"2026-07-31 21:38","pubTimestamp":1785505102,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君圣泰医药-B(02511)发布公告，于2026年7月31日，本公司与独家配售代理订立配售协议，按配售协议的条款及条件，本公司同意发行配售股份，而独家配售代理同意作为本公司的代理，按尽力基准促使不少于六名独立承配人合共认购最多9900万股配售股份，配售价为每股配售股份2.28港元。每股配售股份2.28港元的配售价较于2026年7月31日(即配售协议日期)在联交所所报收市价每股 2.60港元折让约12.31%。假设所有配售股份均获发行，预期配售所得款项总额合共约为2.257亿港元，而预期配售所得款项净额(经扣除与配售有关的佣金及开支后)合共约为 2.23亿港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474881.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655361031","title":"君圣泰医药-B(02511.HK)拟折让约12.31%发行合共最多9900万股配售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2655361031","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655361031?lang=zh_cn&edition=full","pubTime":"2026-07-31 21:38","pubTimestamp":1785505102,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164723718","title":"君圣泰医药-B(02511)拟配售9,900万股 预计募资净额约2.23亿元港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164723718","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164723718?lang=zh_cn&edition=full","pubTime":"2026-07-31 21:35","pubTimestamp":1785504945,"startTime":"0","endTime":"0","summary":"君圣泰医药-B7月31日收市后公告称，公司已与华兴证券（香港）有限公司签订配售协议，拟按每股2.28港元的价格配售最多9,900万股新股份，集资将按“尽力基准”引入不少于六名独立承配人。配售价格2.28港元较7月31日收市价2.60港元折让约12.31%，亦较7月30日前连续五个交易日平均收市价2.576港元折让约11.49%。本次配售预计可筹得资金总额约2.26亿元港元，扣除相关费用后，预计募集资金净额约2.23亿元港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650218243","title":"君圣泰医药-B(02511)：HTD1801随机对照临床研究获积极评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2650218243","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650218243?lang=zh_cn&edition=full","pubTime":"2026-07-10 19:24","pubTimestamp":1783682659,"startTime":"0","endTime":"0","summary":"上述研究结果及社论的发表，进一步体现了HTD1801的临床成果获得国际学术界的广泛关注与认可。基于此，HTD1801有潜力成为CKM领域的基础性治疗药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158238145","title":"君圣泰医药-B6月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1158238145","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158238145?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:53","pubTimestamp":1782982437,"startTime":"0","endTime":"0","summary":"君圣泰医药-B于2026年7月2日公布截至2026年6月30日的股份变动月报表。报告显示，公司期内并无新增发行或股份变动，股本维持稳定。截至本期末，公司已发行股份总数为571,325,668股，暂无库藏股，报告期内未发生任何增发、购回或注销活动。本次月报表由执行董事兼行政总裁刘利平博士签署。根据公告披露，君圣泰医药-B截至2026年6月30日的股本结构与上月保持一致，未有股份发行及回购活动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647328063","title":"格隆汇2026中期策略峰会“All in 硅基新纪元”暨“金格奖”——卓越公司榜单全部揭晓！","url":"https://stock-news.laohu8.com/highlight/detail?id=2647328063","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647328063?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:08","pubTimestamp":1782709733,"startTime":"0","endTime":"0","summary":"本次评选共设有14个奖项","market":"fut","thumbnail":"https://img3.gelonghui.com/9dec8-575c2ec7-abca-4b10-b7d8-3bd3f2cd0682.jpg?guru_height=741&guru_width=1140&guru_size=148310","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/9dec8-575c2ec7-abca-4b10-b7d8-3bd3f2cd0682.jpg?guru_height=741&guru_width=1140&guru_size=148310"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5373783","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["02279","03690","01021","01768","000039","002594","01519","02729","07688","09959","002352","00600","002779","02170","02555","02408","02121","02643","00780","002714","300760","09880","02553","03692","09992","000951","02590","01497","02687","02526","01833","000338","01952","02511","06668","300364","09878","01951","06963","02105","00917","01384","02718","001248","09678","01024","002600","02273","06979","02661"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hightidetx.com","stockEarnings":[{"period":"1week","weight":-0.0188},{"period":"1month","weight":0.0228},{"period":"3month","weight":0.0162},{"period":"6month","weight":0.3083},{"period":"1year","weight":-0.0514},{"period":"ytd","weight":0.0644}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0268},{"period":"3month","weight":0.0023},{"period":"6month","weight":-0.0173},{"period":"1year","weight":-0.0073},{"period":"ytd","weight":-0.0125}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"君圣泰医药是一家生物制药公司，专注于就代谢及消化系统疾病的治疗发现、开发及商业化多功能及多靶点疗法。该公司自主开发了多个候选产品的产品管线，涵盖代谢和消化疾病的多种适应症，其中部分产品处于临床阶段。该公司的核心产品HTD1801（小檗碱熊去氧胆酸盐）是一种新分子实体，作为肠肝抗炎代谢调节剂，靶向调节对人体代谢过程中至关重要的多个通路，包括与代谢及消化系统疾病相关的通路。该公司在美国、中国大陆、香港和澳大利亚开展业务。","exchange":"SEHK","name":"君圣泰医药-B","nameEN":"HIGHTIDE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君圣泰医药-B(02511)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君圣泰医药-B(02511)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君圣泰医药-B,02511,君圣泰医药-B股票,君圣泰医药-B股票老虎,君圣泰医药-B股票老虎国际,君圣泰医药-B行情,君圣泰医药-B股票行情,君圣泰医药-B股价,君圣泰医药-B股市,君圣泰医药-B股票价格,君圣泰医药-B股票交易,君圣泰医药-B股票购买,君圣泰医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君圣泰医药-B(02511)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君圣泰医药-B(02511)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}